Merck’s Cholesterol Pill Receives U.S. FDA Approval

Merck's oral cholesterol-lowering drug, Lipfendra (enlicitide), received FDA approval and is the first of its kind to hit the market. The medication aims to treat high LDL cholesterol by blocking the PCSK9 protein and provides an alternative to injectable options. Approval was based on trials showing significant LDL reductions in various patient groups, with potential for substantial sales.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل